May 19, 2003
GABORONE, Botswana (AP) -- Botswana
is scheduled to begin tests on an AIDS
vaccine to find out if it is safe when
given to healthy adults, officials
said Monday.
The experimental vaccine, which has
already been tested successfully on
mice and rabbits, will be tested to
determine the immune responses of
healthy adults when the drug is given
at different doses, said the Botswana
Harvard AIDS Partnership for HIV
Research and Education.
The vaccine, called EP HIV-1090,
activates the CD8 or killer T cells in
the immune system to destroy cells
infected with HIV, the virus that
causes AIDS.
The trials form the first phase of
the process "to see if the vaccine is
safe and well tolerated in humans,"
said Dr. Tony Villafana, the research
site director.
The study, which is scheduled to
last 18 months, will involve 42
HIV-negative volunteers from Botswana
and the United States.
The test will use only subjects
with high levels of the protein
leukocyte antigen, or HLA, because it
is found to be most responsive to the
treatment.
The drug is made by Epimmune, based
in San Diego, California.
Scientists around the world have
been searching for an effective
vaccine against AIDS for over 20
years. More than 30 experimental
vaccines have been tested with little
success.
In 1999, Uganda became the first
country in Africa to begin testing an
AIDS vaccine on humans. It tested a
vaccine on prostitutes who appeared to
be immune to HIV.
Botswana is the first country on
the continent to commit to a
widespread program of providing AIDS
treatment medicines through its public
health system.
The diamond-rich nation has the
highest HIV-infection rate in the
world, and it has set itself the
target of ending new infections by
2016.
About 19 percent of the country's
1.7 million people are infected with
HIV. An estimated 38 percent of its
adults are infected.
The Botswana Center of Human Rights
has expressed concern over the fact
that there is no local law governing
the way in which clinical trials are
conducted on humans.
Copyright 2003 The Associated
Press. All rights reserved. This
material may not be published,
broadcast, rewritten, or
redistributed.